Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent

Cited 39 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorC W Cho-
dc.contributor.authorY S Cho-
dc.contributor.authorH K Lee-
dc.contributor.authorYoung Il Yeom-
dc.contributor.authorS N Park-
dc.contributor.authorDo Young Yoon-
dc.date.accessioned2017-04-19T08:57:04Z-
dc.date.available2017-04-19T08:57:04Z-
dc.date.issued2000-
dc.identifier.issn0885-4513-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/5096-
dc.description.abstractGene transfer was performed using asialo-orosomucoid-polylysine (ASOR-PL) conjugates to allow targeted expression of the gene in cells of hepatic origin. In a gel-electrophoretic analysis, the ASOR-PL conjugate produced a complete DNA retardation effect at the optimal ratio of 222:1 (ASOR-PL conjugate/pCMVβ-gal plasmid). The gene-transfer efficiency of the ASOR-PL conjugate was evaluated in HepG2 cells that express asialoglycoprotein receptor and NIH 3T3 cells that do not. The expression was assayed by 5-bromo-4-chloroindol-3-yl β-D-galactopyranoside ('X-Gal') staining and Chlorophenol Red β-D-galactopyranoside. When an expression vector for the tumour-suppressor gene p53, pCMVp53, complexed to ASOR-PL conjugate, was transfected into HepG2 cells, the exogenously provided p53 gene was detected in the HepG2 cells by PCR. To improve the efficiency of DNA delivery and expression of the therapeutic proteins poloxamer 407, a fusogenic peptide, influenza-virus haemagglutinin HA2 and chloroquine were individually incorporated into the system. The expression level of β-galactosidase in HepG2 cells was increased by about four times by the presence of poloxamer 407, whereas the fusogenic peptide HA2 and chloroquine had no effects. When HepG2 cells were transfected with pCMVp53 in the presence of poloxamer 407, the mRNA of transfected p53 could be detected by reverse transcriptase PCR. The current findings open the possibility that a receptor-mediated gene-delivery system for hepatic gene therapy using ASOR-PL conjugate in combination with poloxamer 407 may be developed in the future.-
dc.publisherWiley-
dc.titleImprovement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent-
dc.title.alternativeImprovement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent-
dc.typeArticle-
dc.citation.titleBiotechnology and Applied Biochemistry-
dc.citation.number1-
dc.citation.endPage26-
dc.citation.startPage21-
dc.citation.volume32-
dc.contributor.affiliatedAuthorYoung Il Yeom-
dc.contributor.affiliatedAuthorDo Young Yoon-
dc.contributor.alternativeName조정원-
dc.contributor.alternativeName조영식-
dc.contributor.alternativeName이혜경-
dc.contributor.alternativeName염영일-
dc.contributor.alternativeName박순희-
dc.contributor.alternativeName윤도영-
dc.identifier.bibliographicCitationBiotechnology and Applied Biochemistry, vol. 32, no. 1, pp. 21-26-
dc.identifier.doi10.1042/BA20000022-
dc.subject.keywordasialoglycoprotein receptor-
dc.subject.keywordpoloxamer 407-
dc.subject.localAsialoglycoprotein receptor-
dc.subject.localasialogylcoprotein receptor-
dc.subject.localasialoglycoprotein receptor-
dc.subject.localPoloxamer 407-
dc.subject.localpoloxamer 407-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Personalized Genomic Medicine Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.